A Phase 4 interventional study of Omega 3 fatty acid and Placebo in Chronic Periodontitis, sponsored by Tatyasaheb Kore Dental College. Completed at 1 site in India. Open to participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-11-28.
Sponsored by Tatyasaheb Kore Dental College · Phase 4, Interventional, and Treatment
Omega 3 fatty acids is one such dietary supplement, known to modulate the host response in chronic conditions like cardiovascular diseases, rheumatoid arthritis, ischemic cerebrovascular diseases, osteoporosis by producing Resolvins and protectins without showing any inadvertent effects.Addition of systemic Omega 3 Fatty Acids with SRP may enhance the therapeutic result of Chronic Periodontitis owing to host modulation \& anti-inflammatory properties. If proven, this can be used as a routine treatment modality.
1,635 studies on the registry are indexed under Periodontitis; 327 are open to participants now.
This study's enrollment of 60 is above the median of 45 across 1,191 interventional studies indexed under Periodontitis.
Browse Periodontitis studies →Tatyasaheb Kore Dental College is the lead sponsor of 13 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks
Drug: Omega 3 fatty acid
Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks
Drug: Placebo
Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks and SRP at baseline
Also known as: Mega-3
Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks and SRP
Change from baseline in serum CRP level at 6 weeks and 12 weeks
changes from baseline in biochemical parameter, serum CRP levels were assessed at 6 weeks and 12 weeks after starting therapy with omega 3 fatty acids. Serum CRP level was measured in milligram/liter (mg/l)
Time frame: baseline, 6 weeks, 12 weeks
Changes from baseline in pocket depth (PD) at 6 weeks and 12 weeks
changes from baseline in clinical parameter, PD were assessed at 6 weeks and 12 weeks after starting therapy with omega 3 fatty acids. PD was measured in millimeter.
Time frame: baseline, 6 weeks and 12 weeks
Changes from baseline in Clinical Attachment Level (CAL) at 6 weeks and 12 weeks.
changes from baseline in clinical parameter, CAL were assessed at 6 weeks and 12 weeks after starting therapy with omega 3 fatty acids. CAL was measured in millimeter.
Time frame: baseline, 6 weeks and 12 weeks
Changes from baseline in Gingival Index (GI) at 6 weeks and 12 weeks
changes from baseline in standard clinical parameter, GI were assessed at 6 weeks and 12 weeks after starting therapy with omega 3 fatty acids. GI has a scoring criteria specified by Silness \& Loe, 1963.
Time frame: baseline, 6 weeks and 12 weeks
Changes from baseline in Plaque Index (PI) at 6 weeks and 12 weeks
changes from baseline in standard clinical parameter, PI were assessed at 6 weeks and 12 weeks after starting therapy with omega 3 fatty acids. PI has a scoring criteria specified by Loe \& Silness, 1964.
Time frame: baseline, 6 weeks and 12 weeks
Changes from baseline in Oral Hygiene Index Simplified (OHIS) at 6 weeks and 12 weeks.
changes from baseline in standard clinical parameter, OHIS were assessed at 6 weeks and 12 weeks after starting therapy with omega 3 fatty acids. OHIS has a scoring criteria specified by Greene and Vermilion, 1964.
Time frame: baseline, 6 weeks and 12 weeks
Changes from baseline in Sulcus Bleeding Index (SBI) at 6 weeks and 12 weeks
changes from baseline in standard clinical parameter, SBI were assessed at 6 weeks and 12 weeks after starting therapy with omega 3 fatty acids. SBI has a scoring criteria specified by Muhleman (1971).
Time frame: baseline, 6 weeks and 12 weeks
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tatyasaheb Kore Dental College